The Drug Enforcement Administration is allowing more health practitioners prescribe buprenorphine to treat opioid addiction; a public health review found mixed results on the outcome of using e-cigarettes based on age; a new index has graded pharmaceutical companies on how well they are fighting against the spread of superbugs.
As the opioid epidemic continues in the United States, the government has responded by allowing more healthcare practitioners to prescribe buprenorphine, which is used to treat addiction. Reuters reported that the latest change by the Drug Enforcement Administration (DEA) will help open up access to the treatment in rural areas of the country. The DEA is allowing nurse practitioners and physician assistants to become qualifying practitioners to prescribe and dispense buprenorphine.
A public health review has found that outcomes of using e-cigarettes vary depending on the age of the user. Children who use e-cigarettes are more likely to go on to try regular cigarettes, but there is evidence that e-cigarettes help adults quit smoking, according to NPR. The report from the National Academics of Science, Engineering, and Medicine also found that e-cigarettes do contain some harmful byproducts, but less so than regular cigarettes, and that most e-cigarettes still contain nicotine.
A new index is rating pharmaceutical companies on how well they are fighting antibiotic resistance. According to The New York Times, Mylan was named the best generic drug maker and GlaxoSmithKline and Johnson & Johnson were the best of the big companies. The Antimicrobial Resistance Benchmark (ARB) judged companies on several criteria, such as having new antibiotics in development, having measures to encourage prudent use of existing drugs, and clean manufacturing. The British and Dutch governments funded the research that was used to create the ARB.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More